Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 86

Sort by

Sort Order Select

Journal Articles

Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies

Katelyn Purvis, Yinmei Zhou, Seth E. Karol, Jeffrey E. Rubnitz, Raul C. Ribeiro, Shawn HR Lee, Jun J. Yang, W. Paul Bowman, Lu Wang, Stephanie B Dixon, Kathryn G Roberts, Qingsong Gao, Cheng Cheng, Charles G. Mullighan, Sima Jeha, Ching-Hon Pui, Hiroto Inaba

Blood blood.2024024936.

https://doi.org/10.1182/blood.2024024936

Published: 2024

Includes: Supplemental data

Journal Articles

Anti-Leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-Targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBF2AT3::GLIS2 AML

Blood (2023) 142 (Supplement 1): 4295.

https://doi.org/10.1182/blood-2023-180141

Published: 2023

Journal Articles

A Phase I Study of Venetoclax Combined with Homoharringtonine, Cytarabine, and G-CSF for the Treatment of Pediatric De Novo Acute Myeloid Leukemia

Shengqin Cheng, Li Gao, Yi Wang, Peifang Xiao, Hailong He, Jun Lu, Jie Li, Yixin Hu, Liyan Fan, Raul C. Ribeiro, Cheng Cheng, Shaoyan Hu

Blood (2023) 142 (Supplement 1): 2900.

https://doi.org/10.1182/blood-2023-188040

Published: 2023

Journal Articles

GWAS Identifies Variants Associated with Minimal Residual Disease after Induction I in Pediatric Patients with Newly Diagnosed Acute Myeloid Leukemia

Richard J Marrero, Xueyuan Cao, Huiyun Wu, Raul C. Ribeiro, Jeffrey E. Rubnitz, Stanley Pounds, Jatinder K. Lamba

Blood (2023) 142 (Supplement 1): 2967.

https://doi.org/10.1182/blood-2023-179946

Published: 2023

Journal Articles

Relapse-Enriched Gene Expression Signature of Prognostic Relevance in Pediatric Acute Myeloid Leukemia

Satyavardhan Rao Nittu, Francisco Marchi, Nam Nguyen, Vivek M. Shastri, Xueyuan Cao, Raul C. Ribeiro, Jeffrey E. Rubnitz, Alan S Gamis, E. Anders Kolb, Richard Aplenc, Jeffery Klco, Stanley Pounds, Todd A. Alonzo, Soheil Meshinchi, Jatinder K. Lamba

Blood (2023) 142 (Supplement 1): 2926.

https://doi.org/10.1182/blood-2023-189029

Published: 2023

Journal Articles

Leveraging Custom CRISPR/Cas9 Screens to Identify AraC-Daunorubicin-Etoposide (ADE), Gemtuzumab Ozogamicin (GO), and Bortezomib Response Modulators Association with Clinical Outcomes in Pediatric AML

Nam Nguyen, Phani Krishna Parcha, Abderrahmane Tagmount, Bailey Gregory, Jeffrey E. Rubnitz, Raul C. Ribeiro, Xueyuan Cao, Todd A. Alonzo, Richard Aplenc, Alan S Gamis, Todd Cooper, E. Anders Kolb, Soheil Meshinchi, Stanley Pounds, Christopher Vulpe, Jatinder K. Lamba

Blood (2023) 142 (Supplement 1): 1558.

https://doi.org/10.1182/blood-2023-178832

Published: 2023

Journal Articles

Intensification of Therapy and Pharmacogenetic Personalization Mitigate Racial Disparities in Pediatric Acute Myeloid Leukemia Outcomes

Jatinder K. Lamba, Richard J Marrero, Huiyun Wu, Xueyuan Cao, Phani Krishna Parcha, Seth E. Karol, Hiroto Inaba, Dennis John Kuo, Barbara Degar, Kenneth Matthew Heym, Jeffrey Taub, Norman J. Lacayo, Ching-Hon Pui, Raul C. Ribeiro, Stanley Pounds, Jeffrey E. Rubnitz

Blood (2023) 142 (Supplement 1): 386.

https://doi.org/10.1182/blood-2023-173617

Published: 2023

Journal Articles

The Methylome Atlas of Acute Leukemia Enables Novel Clinical Diagnostic Tool for AML

Francisco Marchi, Marieke Landwehr, Fernando Sckaff, Xueyuan Cao, Raul C. Ribeiro, Jeffrey E. Rubnitz, Alan S Gamis, E. Anders Kolb, Richard Aplenc, Stanley Pounds, Todd A. Alonzo, Soheil Meshinchi, Jatinder K. Lamba

Blood (2023) 142 (Supplement 1): 121.

https://doi.org/10.1182/blood-2023-186894

Published: 2023

Journal Articles

Outcomes of Children and Adolescents with Acute Myeloid Leukemia Given a Low-Versus Standard-Dose Chemotherapy Regimen for Remission Induction (CALSIII-AML18): A Multicenter, Phase 3, Randomized, Noninferiority Trial

Blood (2023) 142 (Supplement 1): 729.

https://doi.org/10.1182/blood-2023-189253

Published: 2023

Journal Articles

A Multicenter Clinical Study with Reduced Intensive Chemotherapy for Induction Remission of Pediatric Acute Megakaryoblastic Leukemia

Blood (2023) 142 (Supplement 1): 4276.

https://doi.org/10.1182/blood-2023-190821

Published: 2023

Journal Articles

Decitabine Combined with Low-Dose Chemotherapy Is Effective in the Treatment of Pediatric Refractory/Relapsed Acute Myeloid Leukemia

Liyan Fan, Hua Jiang, Hongjun Liu, Ning Liao, Ningling Wang, Xiaowen Zhai, Xiuli Ju, Yufeng Liu, Jixia Luo, Peifang Xiao, Jun Lu, Hailong He, Yi Wang, Raul C. Ribeiro, Shaoyan Hu

Blood (2023) 142 (Supplement 1): 2905.

https://doi.org/10.1182/blood-2023-191115

Published: 2023

Journal Articles

A DNA Methylation Signature Predicts Clinical Outcome in Pediatric AML Patients

Blood (2023) 142 (Supplement 1): 835.

https://doi.org/10.1182/blood-2023-186505

Published: 2023

Journal Articles

Genome-Wide Association Study Identifies Variants Associated with Clinical Outcomes in Pediatric Patients with Newly Diagnosed Acute Myeloid Leukemia

Richard J Marrero, Xueyuan Cao, Huiyun Wu, Hiroto Inaba, Susana C. Raimondi, Ching-Hon Pui, Raul C. Ribeiro, Jeffrey E. Rubnitz, Stanley B. Pounds, Jatinder K. Lamba

Blood (2022) 140 (Supplement 1): 6295–6296.

https://doi.org/10.1182/blood-2022-159534

Published: 2022

Journal Articles

Single Institution Observational Study of Risk-Adapted Therapy for Children with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia

Yixin Hu, Li Gao, Peifang Xiao, Hailong He, Yi Wang, Liyan Fan, Shengqin Cheng, Jing Ling, Jie Li, Junjie Fan, Yanhua Yao, Xin Ding, Jian Pan, Jun Lu, Raul C. Ribeiro, Shaoyan Hu

Blood (2022) 140 (Supplement 1): 11809.

https://doi.org/10.1182/blood-2022-170708

Published: 2022

Journal Articles

Genome-Wide CRISPR/Cas9 Screen Identifies AraC-Daunorubicin-Etoposide (ADE) Response Modulators Associated with Clinical Outcomes in Pediatric AML

Nam H.K. Nguyen, Abderrahmane Tagmount, Jeffrey E. Rubnitz, Raul C. Ribeiro, Xueyuan Cao, Stanley B. Pounds, Chris D. Vulpe, Jatinder K. Lamba

Blood (2022) 140 (Supplement 1): 5947–5948.

https://doi.org/10.1182/blood-2022-159322

Published: 2022

Journal Articles

A Cibersortx Signature Predicts Outcome in Pediatric AML Patients

Francisco Marchi, Fernando Sckaff, Xueyuan Cao, Raul C. Ribeiro, Jeffrey E. Rubnitz, Stanley B. Pounds, Jatinder K. Lamba

Blood (2022) 140 (Supplement 1): 3441–3442.

https://doi.org/10.1182/blood-2022-163366

Published: 2022

Journal Articles

Proteomic Analysis Identifies Epigenetic Modifiers and Potential Negative Regulators of Leukemogenesis KMD6A and SETDB1 to be Induced Post In Vivo Decitabine Exposure in Pediatric AML

Jatinder K. Lamba, Xueyuan Cao, Huiyun Wu, Hiroto Inaba, Raul C. Ribeiro, Junmin Peng, Tanja A. Gruber, Jeffrey E. Rubnitz, Stanley B. Pounds

Blood (2022) 140 (Supplement 1): 6086–6087.

https://doi.org/10.1182/blood-2022-166671

Published: 2022

Journal Articles

Integrated Gene Expression Analysis Identifies ETS2 Involved in Oncogene Induced Senescence to be Associated with Poor Outcome in Paediatric AML

Phani Krishna Parcha, Xueyuan Cao, Jeffrey E. Rubnitz, Raul C. Ribeiro, Stanley B. Pounds, Jatinder K. Lamba

Blood (2022) 140 (Supplement 1): 11781–11782.

https://doi.org/10.1182/blood-2022-163689

Published: 2022

Journal Articles

PAX5 Epigenetically Orchestrates CD58 Transcription and Modulates Blinatumomab Response in Acute Lymphoblastic Leukemia

Yizhen Li, Takaya Moriyama, Satoshi Yoshimura, Xuijie Zhao, Zhenhua LI, Xu Yang, Jacob A Steele, Shondra Miller, Elisabeth Paietta, Marina Konopleva, Jiyang Yu, Hiroto Inaba, Raul C Ribeiro, Ching-Hon Pui, Jun J. Yang

Blood (2022) 140 (Supplement 1): 1041–1042.

https://doi.org/10.1182/blood-2022-156746

Published: 2022

Journal Articles

Personalization of Induction Therapy for Pediatric AML to Ara-C+Dauno+ Etoposide (ADE) or Clofarabine+Ara-C According to a Polygenic Ara-C SNP Score- ACS10

Jatinder K. Lamba, Richard J Marrero, Abdelrahman H Elsayed, Xueyuan Cao, Huiyun Wu, Hiroto Inaba, Susana C. Raimondi, Ching-Hon Pui, Raul C. Ribeiro, Jeffrey E. Rubnitz, Stanley B. Pounds

Blood (2022) 140 (Supplement 1): 1039–1040.

https://doi.org/10.1182/blood-2022-159657

Published: 2022

NARROW

Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies

Anti-Leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-Targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBF2AT3::GLIS2 AML

A Phase I Study of Venetoclax Combined with Homoharringtonine, Cytarabine, and G-CSF for the Treatment of Pediatric De Novo Acute Myeloid Leukemia

GWAS Identifies Variants Associated with Minimal Residual Disease after Induction I in Pediatric Patients with Newly Diagnosed Acute Myeloid Leukemia

Relapse-Enriched Gene Expression Signature of Prognostic Relevance in Pediatric Acute Myeloid Leukemia

Leveraging Custom CRISPR/Cas9 Screens to Identify AraC-Daunorubicin-Etoposide (ADE), Gemtuzumab Ozogamicin (GO), and Bortezomib Response Modulators Association with Clinical Outcomes in Pediatric AML

Intensification of Therapy and Pharmacogenetic Personalization Mitigate Racial Disparities in Pediatric Acute Myeloid Leukemia Outcomes

The Methylome Atlas of Acute Leukemia Enables Novel Clinical Diagnostic Tool for AML

Outcomes of Children and Adolescents with Acute Myeloid Leukemia Given a Low-Versus Standard-Dose Chemotherapy Regimen for Remission Induction (CALSIII-AML18): A Multicenter, Phase 3, Randomized, Noninferiority Trial

A Multicenter Clinical Study with Reduced Intensive Chemotherapy for Induction Remission of Pediatric Acute Megakaryoblastic Leukemia

Decitabine Combined with Low-Dose Chemotherapy Is Effective in the Treatment of Pediatric Refractory/Relapsed Acute Myeloid Leukemia

A DNA Methylation Signature Predicts Clinical Outcome in Pediatric AML Patients

Genome-Wide Association Study Identifies Variants Associated with Clinical Outcomes in Pediatric Patients with Newly Diagnosed Acute Myeloid Leukemia

Single Institution Observational Study of Risk-Adapted Therapy for Children with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia

Genome-Wide CRISPR/Cas9 Screen Identifies AraC-Daunorubicin-Etoposide (ADE) Response Modulators Associated with Clinical Outcomes in Pediatric AML

A Cibersortx Signature Predicts Outcome in Pediatric AML Patients

Proteomic Analysis Identifies Epigenetic Modifiers and Potential Negative Regulators of Leukemogenesis KMD6A and SETDB1 to be Induced Post In Vivo Decitabine Exposure in Pediatric AML

Integrated Gene Expression Analysis Identifies ETS2 Involved in Oncogene Induced Senescence to be Associated with Poor Outcome in Paediatric AML

PAX5 Epigenetically Orchestrates CD58 Transcription and Modulates Blinatumomab Response in Acute Lymphoblastic Leukemia

Personalization of Induction Therapy for Pediatric AML to Ara-C+Dauno+ Etoposide (ADE) or Clofarabine+Ara-C According to a Polygenic Ara-C SNP Score- ACS10

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only